YL217

· MediLink Therapeutics (Suzhou) Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for YL217, covering 2026-01-14 to 2026-01-14. Get the full timeline:

Most recent: Clinical Trial Update: A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors [Phase 1]